Immune checkpoint combinations from mouse to man. (Q38306150)

2 September 2017

1 reference

title

Immune checkpoint combinations from mouse to man. (English)

1 reference

2 September 2017

Michael A Curran

2

0 references

author name string

Midan Ai

series ordinal

1

1 reference

2 September 2017

language of work or name

1 reference

3 January 2015

1 reference

Cancer Immunology, Immunotherapy

2 September 2017

published in

1 reference

2 September 2017

volume

64

1 reference

2 September 2017

issue

7

1 reference

2 September 2017

page(s)

885-892

1 reference

Über den jetzigen Stand der Chemotherapie

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytes choriomeningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Clinical targeting of the TNF and TNFR superfamilies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Targeting the B7 family of co-stimulatory molecules: successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Increased frequency of ICOS CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

4-1BB as a therapeutic target for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

4-1BB Triggering Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Balance between Th17 and Regulatory T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Humanized mice as a model for aberrant responses in human T cell immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-014-1650-8

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1007/S00262-014-1650-8

1 reference

Dimensions Publication ID

2 September 2017

1028266972

0 references

1 reference